← Eichor
Condition: Stage Ii Lung Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Stage Ii Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subje
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07175220A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the L
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05354570TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2 · 1 location(s) · TYK Medicines, Inc · NCT05948813Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Phase 2 · 3 location(s) · Hackensack Meridian Health · NCT05715229A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06694454Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05419076Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06554613IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: RO
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT01639508A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Chinese University of Hong Kong · NCT07379476AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05377658Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Phase N/A · 3 location(s) · Vanderbilt-Ingram Cancer Center · NCT00897117A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437509WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06243003Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06014827Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · The Canadian College of Naturopathic Medicine · NCT05849129A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05924841Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After R
Phase N/A · 1 location(s) · Liaoning Cancer Hospital & Institute · NCT06109454A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 103 location(s) · AstraZeneca · NCT06996782Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07528274A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 · 2 location(s) · Shanghai Henlius Biotech · NCT06907615Pembrolizumab for Advanced NSCLC and PS 2-3
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05589818
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.